TNO155

Phase 2Small molecule

Novartis

TNO155 is one of 129 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

EGFRTerminated

Non-Small Cell Lung CarcinomaRecruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

EGFRPhase 1

Terminated

Non-Small Cell Lung CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

TNO155

Novartis

Phase 2

1 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Imjudo

AstraZeneca

Preclinical

5 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

Immunotherapy

Remeron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT04185883

Q3 2029

PreclinicalRecruiting

Non-Small Cell Lung Carcinoma

NCT07468071

Clinical

Trials by Indication[1]

Renal Impairment1 trial

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Withdrawn· Novartis logo

Novartis·Phase 1·NCT05541159

Hepatic Impairment1 trial

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Withdrawn· Novartis logo

Novartis·Phase 1·NCT05490030

Colorectal Cancer1 trial

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Terminated· Novartis logo

Novartis·Phase 1·NCT04294160·122 enrolled

Lung Cancer1 trial

Lorlatinib Combinations in Lung Cancer

Unknown status·MMassachusetts General Hospital·Phase 1/2·NCT04292119·96 enrolled

Cancer1 trial

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Completed·MMirati Therapeutics Inc.·Phase 1·NCT04330664·86 enrolled

5 more indications

Advanced Solid Tumors1 trial

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT04185883·610 enrolled

Malignancies1 trial

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Terminated· Novartis logo

Novartis·Phase 1·NCT04000529·122 enrolled

Non-Small Cell Lung Carcinoma1 trial

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Recruiting· Novartis logo

Novartis·Preclinical·NCT07468071·40 enrolled

EGFR1 trial

An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

Terminated· Novartis logo

Novartis·Phase 1·NCT03114319·227 enrolled

Non-Small Cell Lung Cancer1 trial

GEOMETRY Mono-1 Ext: Capmatinib in METex14 NSCLC

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT04699188·373 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for TNO155. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TNO155 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TNO155. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

TNO155

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Renal Impairment1 trial

Hepatic Impairment1 trial

Colorectal Cancer1 trial

Lung Cancer1 trial

Cancer1 trial

Advanced Solid Tumors1 trial

Malignancies1 trial

Non-Small Cell Lung Carcinoma1 trial

EGFR1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News